Citalopram vs. Sertraline: Key Differences Explained

Compare Citalopram and Sertraline beyond their shared class. Get clarity on their distinct attributes for managing mental health.

Citalopram and sertraline are both selective serotonin reuptake inhibitors prescribed for depression, and in direct comparisons they produce similar improvements in mood. Where they part ways is in their side-effect profiles, how they interact with other medications, their safety during pregnancy and breastfeeding, and their effects on heart rhythm. Those differences, rather than raw antidepressant power, are usually what tips the decision toward one or the other.

A Slightly Different Grip on Serotonin

Both drugs work by blocking the serotonin transporter, the protein that pulls serotonin back into nerve cells after it has been released. The result is more serotonin lingering in the gap between neurons, which over time leads to the mood-lifting effects people rely on. But citalopram is one of the most serotonin-selective SSRIs available. It binds tightly to the serotonin transporter and has very little affinity for other targets. Sertraline, by contrast, has moderate affinity for the dopamine transporter as well, meaning it can mildly increase dopamine signaling alongside its serotonin effects. Whether that extra dopamine activity translates into a noticeable clinical advantage for any specific symptom remains debatable, but some clinicians feel sertraline can help more with fatigue and motivation for this reason.

How They Stack Up for Depression

The most reassuring finding for anyone trying to choose between the two is that head-to-head trials consistently show similar overall results. A placebo-controlled trial comparing the drugs found that both produced significantly greater improvement than placebo on standard depression scales. Citalopram appeared to show improvement at slightly earlier time points, but that advantage faded once early dropouts (more common with sertraline, mainly due to stomach trouble) were excluded from the analysis. A separate randomized, double-blind trial measuring depression outcomes alongside a biomarker called BDNF found no significant differences between the two drugs, though there was a hint that men and women might respond somewhat differently at the biological level.

One pragmatic open-label comparison did find a modest edge for citalopram in terms of how many patients achieved remission. Open-label means the participants knew which drug they were taking, which can subtly influence results. Still, the pattern across the evidence is one of rough equivalence. If you respond poorly to one, switching to the other is reasonable, but the probability of a dramatic difference is low.

Beyond Depression

Both drugs are prescribed off-label for anxiety-related conditions, though sertraline carries formal approvals for a wider range of conditions in most countries, including panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Citalopram is mainly approved for major depression and is used off-label for generalized anxiety and panic. A large network meta-analysis pooling data across anxiety, OCD, and stress disorders found that for an aggregate measure of anxiety-type symptoms, escitalopram (the refined version of citalopram) and paroxetine outperformed sertraline, while no significant differences emerged for OCD symptoms specifically. That finding involves escitalopram rather than citalopram itself, so the comparison is not perfectly clean, but it suggests the citalopram family may hold a slight edge for some anxiety presentations.

Stomach Side Effects

If you have a sensitive stomach, this section matters. Nausea, diarrhea, and general GI discomfort are common with all SSRIs, but sertraline is consistently among the worst offenders. A network meta-analysis of GI side effects across twenty antidepressants found sertraline carried about a threefold increase in the odds of nausea compared with placebo, while citalopram’s odds were roughly two-and-a-half times placebo. The gap is not enormous, but if you already deal with irritable bowel symptoms or nausea-prone conditions, it could make citalopram the more comfortable choice.

GI side effects with both drugs tend to peak in the first week or two and then fade. Starting at a low dose and taking the medication with food can blunt the initial stomach upset. For some people on sertraline, loose stools persist longer-term, a quirk that seems connected to serotonin’s role in gut motility.

Sexual Side Effects

Sexual dysfunction is probably the side effect that drives the most frustration and the most medication switches. All SSRIs can dampen desire, delay orgasm, or interfere with arousal, but the pattern is not identical across drugs. A pharmacovigilance analysis of adverse-event reports found that sertraline had the broadest spectrum of sexual side effects among the SSRIs studied, with fifteen distinct signal types detected, the strongest being loss of libido. Citalopram and escitalopram followed closely, and they were the only drugs in the analysis linked to female orgasmic disorder specifically.

So neither drug wins this category cleanly. Sertraline casts a wider net of possible sexual problems, but citalopram has its own liabilities. If sexual function is a high priority and one drug is causing trouble, it is worth trying the other or discussing a non-SSRI alternative with your prescriber rather than assuming all SSRIs will feel the same.

Heart Rhythm Concerns

This is one of the sharper practical differences between the two. Citalopram is associated with dose-dependent QTc prolongation, a change in the heart’s electrical timing that can, in rare cases, trigger dangerous arrhythmias. Regulatory agencies in several countries have capped the recommended dose of citalopram at 40 mg per day for most adults and 20 mg per day for people over 60. Sertraline does not carry the same concern. A review of the QTc data across SSRIs concluded that sertraline, along with fluoxetine and fluvoxamine, shows a low risk of clinically significant QTc prolongation, even in patients recovering from heart attacks.

If you have a history of heart rhythm problems, take other medications known to lengthen QTc (certain antibiotics, antipsychotics, or anti-nausea drugs), or are an older adult where cardiac risk is higher, sertraline is generally the safer pick. Citalopram is not dangerous for most healthy younger adults at standard doses, but the dose ceiling can become a practical limitation if you need a higher amount for adequate symptom control.

Drug Interactions

The liver enzymes that break down medications vary from one SSRI to another, and this is where citalopram has a genuine advantage. Citalopram has very little inhibitory effect on the major liver enzymes responsible for metabolizing other drugs. Sertraline is a moderate inhibitor of the CYP2D6 enzyme, which processes a long list of medications including certain beta-blockers, antipsychotics, opioid painkillers like codeine and tramadol, and some antihistamines.

In practice, sertraline’s CYP2D6 effect is milder than that of paroxetine or fluoxetine, so it is still considered relatively interaction-friendly among SSRIs. But if you take several other medications and your prescriber wants to minimize the chance of unexpected drug interactions, citalopram’s clean interaction profile is a real asset. This is one reason citalopram has been popular in hospital settings and among patients with complex medication regimens.

Pregnancy and Breastfeeding

For pregnant or nursing women who need an antidepressant, sertraline is usually the first option offered. It crosses the placenta less readily than most other SSRIs, resulting in fetal concentrations roughly a third of maternal levels. Citalopram, by contrast, reaches the highest concentrations in amniotic fluid of any SSRI. A review of the broader safety literature found that both sertraline and citalopram have a generally favorable track record compared with paroxetine and fluoxetine, which show stronger associations with birth complications, but the data supporting sertraline’s safety is larger and more consistent.

For breastfeeding specifically, sertraline passes into breast milk in the smallest amounts among the SSRIs. That said, individual responses vary. There is at least one published case of an infant who could not tolerate sertraline exposure through breast milk but did fine when the mother switched to citalopram. A single case report does not overrule population-level evidence, but it illustrates that the “safest SSRI in lactation” question can have a different answer for a particular mother and baby. The principle remains: sertraline is the default, and citalopram is a reasonable alternative if it is not tolerated.

Considerations for Older Adults

Prescribing an SSRI in people over 60 or 65 involves a few extra factors. The QTc issue with citalopram is more consequential here because older adults are more likely to have underlying cardiac conditions or to be taking other QTc-prolonging medications. The dose cap of 20 mg per day for older adults limits how much room a prescriber has to optimize the dose. Sertraline does not have an equivalent cardiac dose restriction, making it easier to titrate upward if needed.

One concern shared by both drugs is hyponatremia, an abnormal drop in blood sodium levels. This is a class-wide effect of SSRIs, not unique to either citalopram or sertraline, but older adults are the ones most at risk because of age-related changes in kidney function and the frequent use of diuretics. Checking a sodium level before starting and keeping an eye out for confusion or unsteadiness after initiation is standard practice. Neither drug is clearly worse than the other for this risk; it is more a matter of clinical vigilance with any SSRI in this age group.

What Equivalent Doses Look Like

Citalopram and sertraline are not milligram-for-milligram substitutes. Typical starting doses are 20 mg for citalopram and 50 mg for sertraline, and effective doses often land around 20 to 40 mg for citalopram and 50 to 200 mg for sertraline. A dose-equivalence analysis based on randomized trial data estimated that about 100 mg of sertraline is equivalent to roughly 40 mg of fluoxetine. Citalopram’s equivalent sits in a similar range, typically 20 to 40 mg mapping onto the same therapeutic window, though the ceiling is capped by the QTc concern already discussed.

If you are switching from one to the other, the transition is usually straightforward. Many prescribers use a cross-taper, gradually reducing one while slowly introducing the other over a week or two. Because both are SSRIs, the risk of serotonin syndrome during a switch is low as long as there is no period of double-dosing. Still, it is worth doing under guidance rather than swapping on your own.

Cost and Generic Availability

Both citalopram and sertraline have been available as generics since the mid-2000s, and their prices are among the lowest of any antidepressant. A comparison of US Medicare data found that a month’s supply of generic sertraline at a therapeutic dose cost around $16, while a month of generic citalopram was about $27. Those figures are from Medicare pricing and will vary depending on your insurance and pharmacy, but the overall picture holds: both are inexpensive and widely stocked. Cost is rarely the deciding factor between them. If it were, sertraline has a slight edge, and both are far cheaper than brand-name escitalopram (Lexapro), the refined cousin of citalopram that remained patent-protected longer.

Effects on Weight and Metabolism

Weight gain on SSRIs is a common worry, and the answer is frustratingly individual. Short-term trials generally do not show dramatic weight changes with either drug, but longer use (a year or more) can bring modest gains for some people. A laboratory study looking at both citalopram and sertraline found that each drug increased lipid accumulation in fat cells in a dose-dependent fashion, with disruption to normal fat-cell metabolism that could theoretically push the body toward dysfunctional fat storage. That research was done in cell models, not in people, so it is far too early to draw clinical conclusions. But it does suggest a plausible mechanism by which either drug could contribute to metabolic changes over time. Neither drug stands out as clearly better or worse than the other on this front.

How They Were Developed

The two drugs emerged from different research groups within a few years of each other. Citalopram was synthesized in 1972 by a Danish chemist and first reached the market in Denmark in 1989. Sertraline’s development started in 1977 at Pfizer, led by a pharmacologist and a chemist, and it launched in the UK in 1990. Both arrived as part of the wave of SSRIs that replaced older tricyclic antidepressants as first-line treatment, offering a cleaner side-effect profile and much lower overdose risk. Sertraline went on to become one of the most prescribed medications in the world, partly because of its broad approval for anxiety conditions. Citalopram carved out its own niche, and its refined version, escitalopram, eventually became a blockbuster in its own right.

The fact that both drugs have been in wide clinical use for over thirty years means the safety data is deep. Rare side effects that take years to surface have had ample time to show up in pharmacovigilance databases. For a patient or prescriber, that long track record provides more confidence than you get with newer medications where the post-marketing data is still accumulating.

Sleep Effects

SSRIs as a class tend to disrupt sleep architecture. Sleep studies have shown that these drugs reduce REM sleep, lengthen the time it takes to fall asleep, and increase nighttime awakenings. Neither citalopram nor sertraline is dramatically different from the other in this regard. Some people find sertraline slightly more activating and prefer to take it in the morning, while others report that citalopram causes daytime drowsiness. These experiences are highly individual and do not follow a reliable pattern across the population. If sleep disruption is a persistent problem with one, the other is worth trying, but expectations should be moderate since both act on the same neurotransmitter system.

One practical tip: taking either drug at a consistent time each day and allowing six to eight weeks for sleep to stabilize can help. Early insomnia on an SSRI often improves as the antidepressant effect kicks in and depression-related sleep problems resolve.